Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


02.06.2025

1 Am J Respir Crit Care Med
1 Ann Surg Oncol
1 Anticancer Res
6 BMC Cancer
1 Clin Exp Metastasis
1 Clin Lung Cancer
1 Eur J Cardiothorac Surg
1 Int J Oncol
1 J Surg Oncol
2 J Thorac Oncol
2 JAMA Oncol
3 Lung Cancer
1 Mol Cancer Ther
1 Nat Med
1 Oncol Rep
2 PLoS One
1 Semin Oncol
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. GARSHICK E
    Lung Cancer and the Environment.
    Am J Respir Crit Care Med. 2025.
    PubMed        


    Ann Surg Oncol

  2. NAEEM W, Khan AA, Adebayo OW, Ansari M, et al
    ASO Visual Abstract: Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer.
    Ann Surg Oncol. 2025 May 26. doi: 10.1245/s10434-025-17521.
    PubMed        


    Anticancer Res

  3. OKUNO T, Hongoh M, Tanino R, Okimoto T, et al
    Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety.
    Anticancer Res. 2025;45:2551-2561.
    PubMed         Abstract available


    BMC Cancer

  4. WU S, Qiu Z, Shi H, Yu W, et al
    High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy.
    BMC Cancer. 2025;25:926.
    PubMed         Abstract available

  5. TAN M, Li L, Tan B, Yang J, et al
    Innovations in modern low-LET radiotherapy regimens for locally advanced non-small cell lung cancer: a meta-analysis and systematic review of high-dose-rate brachytherapy, stereotactic body radiotherapy, and hypofractionated proton therapy.
    BMC Cancer. 2025;25:942.
    PubMed         Abstract available

  6. CHEN H, Yu Y, Zhu S, Zhao J, et al
    Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
    BMC Cancer. 2025;25:948.
    PubMed         Abstract available

  7. MENG H, Ding RQ, Jia L, Chen XP, et al
    Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.
    BMC Cancer. 2025;25:960.
    PubMed         Abstract available

  8. XING H, Wu C, Yang W, Cai S, et al
    Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.
    BMC Cancer. 2025;25:954.
    PubMed         Abstract available

  9. RENAUD S, Casabianca P, Diez-Andreu P, Chartier M, et al
    Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study.
    BMC Cancer. 2025;25:966.
    PubMed         Abstract available


    Clin Exp Metastasis

  10. YANG X, Chu X, Ye R, Ni J, et al
    Oligo-residual disease in metastatic ALK-positive NSCLC treated with alectinib.
    Clin Exp Metastasis. 2025;42:31.
    PubMed         Abstract available


    Clin Lung Cancer

  11. JOSEPHIDES E, Daddi N, Bertoglio P, Lugaresi M, et al
    A Propensity-Matched Comparison Between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage IA Non-Small-Cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Apr 29:S1525-7304(25)00083.
    PubMed         Abstract available


    Eur J Cardiothorac Surg

  12. NAKADA T, Suyama Y, Otani A, Tsukamoto Y, et al
    Resection of 4 or more pulmonary segments increases the risk of non-cancer-related mortality.
    Eur J Cardiothorac Surg. 2025;67:ezaf162.
    PubMed         Abstract available


    Int J Oncol

  13. SHEN W, Pang H, Xin B, Duan L, et al
    [Corrigendum] Biological effects of BMP7 on small?cell lung cancer cells and its bone metastasis.
    Int J Oncol. 2025;66:51.
    PubMed         Abstract available


    J Surg Oncol

  14. KUSAMURA S, Cinquini M, Morris D, Piso P, et al
    Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation.
    J Surg Oncol. 2025;131:810-815.
    PubMed         Abstract available


    J Thorac Oncol

  15. HERBST RS, Cho BC, Zhou C, Burotto M, et al
    Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: Phase 3 LEAP-006 Study.
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00724.
    PubMed         Abstract available

  16. CHADDHA U, Agrawal A, Ghori U, Kheir F, et al
    Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology (AABIP) and International Association for the Study of Lung Cancer (IASLC) Clinical Practic
    J Thorac Oncol. 2025 May 24:S1556-0864(25)00722.
    PubMed         Abstract available


    JAMA Oncol

  17. MARINELLO A, Ghigna MR, Rotow JK, Adeyelu T, et al
    Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1293.
    PubMed         Abstract available

  18. ROLLE LD
    Coding Errors in Study of Lung Cancer Screening Guidelines and Adherence.
    JAMA Oncol. 2025 May 29. doi: 10.1001/jamaoncol.2025.1624.
    PubMed        


    Lung Cancer

  19. MATSUBARA T, Shimokawa M, Wakasu S, Haro A, et al
    Controlling nutritional status predicts postoperative survival and acute exacerbation in resected non-small cell lung cancer with interstitial lung disease.
    Lung Cancer. 2025;205:108591.
    PubMed         Abstract available

  20. MOORE WH, Silk M, Bhattacharji P, Pua BB, et al
    Early experience with PEF in the setting of recalcitrant stage IV lung cancer.
    Lung Cancer. 2025;204:108575.
    PubMed         Abstract available

  21. NOMURA S, Sekino Y, Shiraishi Y, Toi Y, et al
    A treatment-related death predictive score for treatment-naive advanced non-small cell lung cancer.
    Lung Cancer. 2025;204:108584.
    PubMed         Abstract available


    Mol Cancer Ther

  22. OKAWA S, Tomida S, Kuribayashi T, Nishimura J, et al
    Colony-stimulating factor-1 receptor inhibitor augments osimertinib-induced anti-tumor immunity via suppression of macrophages in lung cancer harboring EGFR mutation.
    Mol Cancer Ther. 2025 May 29. doi: 10.1158/1535-7163.MCT-25-0002.
    PubMed         Abstract available


    Nat Med

  23. SKOULIDIS F, Li BT, de Langen AJ, Hong DS, et al
    Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer.
    Nat Med. 2025 May 28. doi: 10.1038/s41591-025-03732.
    PubMed         Abstract available


    Oncol Rep

  24. ZINNAH KMA, Park SY
    [Corrigendum] Sensitizing TRAIL?resistant A549 lung cancer cells and enhancing TRAIL?induced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2025;54:87.
    PubMed         Abstract available


    PLoS One

  25. PEREZ AL, Zamora M, Bahena M, Aramburo-Williams R, et al
    The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.
    PLoS One. 2025;20:e0316983.
    PubMed         Abstract available

  26. ZHANG Y, Hu Y, Xi J, Wu B, et al
    Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0319357.
    PubMed         Abstract available


    Semin Oncol

  27. TEGAW EM, Asfaw BB
    Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer.
    Semin Oncol. 2025;52:152364.
    PubMed         Abstract available


    Thorax

  28. ZHANG L, Wang X, Chen Q, Zhao M, et al
    Lung cancer risk assessment by prediction model: a global perspective.
    Thorax. 2025 May 27:thorax-2023-221253. doi: 10.1136/thorax-2023-221253.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.